SCHEMBL9941695

SCHEMBL9941695

CC1(C)COB(c2cc(Cl)ccc2C#N)OC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCAM1 P19320 1/20 0.36
NOS3 P29474 9/20 0.33
NOS1 P29475 9/20 0.33
NOS2 P35228 9/20 0.33
MAOA P21397 2/20 0.33
MAOB P27338 2/20 0.33
GPR35 Q9HC97 1/20 0.33
CYP2A6 P11509 1/20 0.33
AR P10275 2/20 0.32
MEN1 O00255 2/20 0.32
ALDH1A1 P00352 2/20 0.32
KMT2A Q03164 2/20 0.32
NR3C1 P04150 1/20 0.32
PGR P06401 1/20 0.32
LMNA P02545 1/20 0.32
HTT P42858 1/20 0.32
KDM4E B2RXH2 2/20 0.31
MAPT P10636 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12299446 0.84 POLB (0.32) AR
SCHEMBL21635295 0.84 AR (0.32) AR
SCHEMBL13183400 0.80 VCAM1 (0.38) VCAM1NOS3NOS1NOS2MAOA
SCHEMBL21083818 0.79 CYP11B1 (0.38) MAOAMAOBARALDH1A1LMNA
SCHEMBL12246952 0.79
SCHEMBL2658949 0.78 ICMT (0.30)
SCHEMBL4491246 0.78 TSHR (0.37) ARALDH1A1HTTKDM4EHPGD
SCHEMBL31048086 0.78 TSHR (0.37) ARALDH1A1HTTKDM4EHPGD
SCHEMBL5892425 0.75 ALDH1A1 (0.39) MEN1ALDH1A1KMT2ALMNAKDM4E
SCHEMBL2659671 0.75 CA1 (0.34) GPR35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037324-B2 Biarylmethyl heterocycles BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-16 US disclosed
EP-3478672-B1 BIARYLMETHYL HETEROCYCLES UNIV MONTREAL (CA) 2024-04-10 EP disclosed
US-20230045357-A1 BIARYLMETHYL HETEROCYCLES Université de Montréal (CA) 2023-02-09 US disclosed
US-11407733-B2 Biarylmethyl heterocycles BRISTOL-MYERS SQUIBB COMPANY (US) 2022-08-09 US disclosed
US-20190202808-A1 BIARYLMETHYL HETEROCYCLES BRISTOL-MYERS SQUIBB COMPANY 2019-07-04 US disclosed
EP-3478672-A1 BIARYLMETHYL HETEROCYCLES Université de Montréal (CA) 2019-05-08 EP disclosed
WO-2018005591-A1 BIARYLMETHYL HETEROCYCLES UNIVERSITE DE MONTREAL (CA) 2018-01-04 WO disclosed
EP-2651899-B1 SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF HOFFMANN LA ROCHE (CH) 2017-05-31 EP disclosed
US-20160060262-A1 Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof GENENTECH, INC. (US) 2016-03-03 US disclosed
US-9206175-B2 Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof GENENTECH, INC. (US) 2015-12-08 US disclosed
US-20140088076-A1 SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2014-03-27 US disclosed
US-8623889-B2 Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof GENENTECH, INC. (US) 2014-01-07 US disclosed
EP-2651899-A2 SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF F.HOFFMANN-LA ROCHE AG (CH) 2013-10-23 EP disclosed
US-20120322785-A1 SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2012-12-20 US disclosed
WO-2012080284-A2 SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407733-B2 Biarylmethyl heterocycles ARRB1, ADRB2, ADRB1 VCAM1 1721/4885NOS3 1783/4885NOS1 2727/4885
US-20190202808-A1 BIARYLMETHYL HETEROCYCLES ARRB1, ADRB2, ADRB1 VCAM1 1721/4885NOS3 1783/4885NOS1 2727/4885
US-20160060262-A1 Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof XDH, CYP2B6, COX6B1 VCAM1 4827/4885NOS3 50/4885NOS1 209/4885
US-20120322785-A1 SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF XDH, CYP2B6, COX6B1 VCAM1 4827/4885NOS3 50/4885NOS1 209/4885
US-20140088076-A1 SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF XDH, CYP2B6, COX6B1 VCAM1 4827/4885NOS3 50/4885NOS1 209/4885
US-12037324-B2 Biarylmethyl heterocycles ARRB1, ADRB2, ADRB1 VCAM1 1721/4885NOS3 1783/4885NOS1 2727/4885
US-20230045357-A1 BIARYLMETHYL HETEROCYCLES ARRB1, ADRB2, ADRB1 VCAM1 1721/4885NOS3 1783/4885NOS1 2727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.